Why the QPPV Matters More Than Ever

New safety information emerges as treatments reach patients, with adverse reactions being reported and benefit-risk assessments changing. Pharmaceutical and biotechnology companies must ensure that their pharmacovigilance systems can respond effectively while meeting regulatory obligations across markets.

At the centre of this responsibility is the Qualified Person Responsible for Pharmacovigilance (QPPV).

Traditionally associated with regulatory compliance and safety reporting oversight, the QPPV's role is increasingly important in connecting pharmacovigilance operations, quality management, safety information and organisational decision-making.

For companies expanding into new markets or outsourcing drug safety activities, appointing a QPPV is only the starting point. The real priority is establishing an effective arrangement that supports continuous oversight, timely escalation and a well-functioning pharmacovigilance system.

What Is a QPPV in Pharmacovigilance?

A Qualified Person Responsible for Pharmacovigilance (QPPV) is the designated individual responsible for overseeing a marketing authorisation holder's pharmacovigilance system under the applicable regulatory framework.

In the European Union, marketing authorisation holders must have a QPPV permanently and continuously at their disposal. The QPPV has defined responsibilities relating to the functioning of the pharmacovigilance system, product safety profiles and applicable regulatory obligations.

Depending on the jurisdiction, additional or different requirements may apply. Companies must distinguish between EU QPPV requirements, UK requirements and local pharmacovigilance contact arrangements in other markets.

For medicinal products authorized in the UK, the MAH must have permanently and continuously at its disposal an appropriately qualified QPPV who resides and operates in the UK or EU/EEA. Where the QPPV does not reside and operate in the UK, a UK National Contact Person (NCP) for Pharmacovigilance is also required. The applicable UK PSMF should also be reflected in the pharmacovigilance system.

The QPPV's effectiveness depends on having appropriate qualifications, access to relevant safety information, organisational authority and the resources needed to fulfil the role.

What Are the Key Responsibilities of a QPPV?

QPPV responsibilities extend across several essential areas of pharmacovigilance.

1. Pharmacovigilance system oversight
The QPPV maintains appropriate oversight of the pharmacovigilance system, including relevant processes, quality arrangements, outsourced activities and compliance information.

2. Product safety and benefit-risk monitoring
The QPPV must have an appropriate overview of the safety profiles of relevant medicinal products. Emerging safety concerns must be evaluated and escalated through established processes.

3. Regulatory reporting oversight
The pharmacovigilance system must support applicable reporting obligations, including individual case safety reports (ICSRs), Periodic Safety Update Reports (PSURs) and other required safety documentation, as relevant to the product and jurisdiction.

4. Pharmacovigilance System Master File (PSMF)
The QPPV has important responsibilities relating to the functioning of the pharmacovigilance system described in the PSMF. The documentation must accurately reflect the system's organisation and operation.

5. Inspection readiness and quality management
The QPPV's oversight supports appropriate management of audit findings, corrective and preventive actions (CAPAs), compliance issues and inspection responses.

1. Is a QPPV mandatory for pharmaceutical companies?

Requirements depend on the jurisdiction. For example, EU marketing authorisation holders must have a QPPV permanently and continuously at their disposal. Companies should confirm the applicable requirements for each market.

Why Are Companies Rethinking Their QPPV Arrangements?

The growing complexity of pharmaceutical development and commercialisation is increasing the importance of effective pharmacovigilance oversight.

• Expanding into global markets
  Companies operating across multiple markets must manage different regulatory expectations, local requirements and reporting arrangements. A QPPV strategy must reflect the requirements of each relevant market rather than assume that one appointment fulfils every obligation.
• Managing increasingly complex safety information
  Safety information may originate from spontaneous reports, clinical trials, medical literature and other relevant sources. Organisations need processes that support accurate data capture, timely assessment and appropriate escalation. Technology can improve workflow efficiency and information access, but it must operate within appropriate quality and governance frameworks.

Can QPPV Services Be Outsourced?

Outsourced QPPV services can be an option where permitted by the applicable regulatory framework and where the arrangement meets all relevant requirements.

This model may benefit biotechnology companies, smaller marketing authorisation holders and pharmaceutical organisations entering new markets or strengthening existing pharmacovigilance capabilities.

Potential benefits include:

• Access to specialist pharmacovigilance expertise.
• Greater flexibility as product portfolios and market requirements evolve.
• Support for pharmacovigilance system oversight and inspection readiness.
• Coordination with broader pharmacovigilance operations, where included in the service scope.

How Should You Choose a QPPV Service Provider?

Companies should evaluate whether the proposed arrangement can support their regulatory requirements and operating model.

Key considerations include:

• Regulatory expertise: Does the provider understand the requirements of the relevant jurisdictions?
• System oversight: Can the QPPV access the safety information and compliance data needed to fulfil the role?
• Inspection readiness: Can the arrangement support PSMF oversight, inspection responses and CAPA follow-up?
• Communication: Are escalation pathways and responsibilities clearly documented?
• Continuity: Are appropriate backup and continuity arrangements established?
• Operational integration: Can the QPPV work effectively with internal teams and outsourced pharmacovigilance providers?

The right arrangement should integrate regulatory accountability with the practical functioning of the pharmacovigilance system.

How does a QPPV support inspection readiness?

The QPPV's oversight helps the organisation maintain appropriate pharmacovigilance processes, documentation, compliance monitoring and quality management, supporting its ability to demonstrate that the system functions effectively.

How Can Navitas Life Sciences Support Your QPPV Requirements?

Effective QPPV arrangements require a structured approach to oversight, access to relevant safety information, clear communication and alignment with the organisation's pharmacovigilance processes.

Navitas Life Sciences provides pharmacovigilance services to support pharmaceutical and biotechnology companies in managing drug safety and regulatory requirements.

When evaluating QPPV support, organisations should consider how the proposed services align with their product portfolios, target markets, existing systems and wider pharmacovigilance needs.

The QPPV is a critical component of an effective pharmacovigilance system, connecting product safety oversight, regulatory compliance and quality management.

 

For pharmaceutical and biotechnology companies operating across markets or relying on outsourced activities, the priority is to establish a QPPV arrangement that is appropriately resourced, integrated and aligned with applicable regulations.

 

Reach out to us to explore an approach aligned with your products, markets and drug safety requirements.

Learn more about our services and solutions by reaching out to us at This email address is being protected from spambots. You need JavaScript enabled to view it..